 Home > Medical News > Latest Medical News > Another new crown drug phase III clinical failure company's share price plummeted 80%

Another new crown drug phase III clinical failure company's share price plummeted 80%

 Last Update: 2022-05-28
 Source: Internet
 Author: User

Tags

companies carbon neutral

produce oxygen

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On February 21, Synairgen announced that the international Phase III SPRINTER clinical trial of SNG001 in hospitalized patients with new coronary pneumonia did not meet its primary or key secondary efficacy endpoints, but demonstrated a favorable safety profile and was well tolerated in this population

SNG001 is a naturally occurring broad-spectrum antiviral protein interferon beta that can be directly inhaled into the lungs to stimulate the body to produce an immune response

SPRINTER is a randomized, double-blind, placebo-controlled, international Phase III clinical trial designed to evaluate the efficacy and safety of SNG001 in the treatment of hospitalized patients with moderate COVID-19

The results showed that patients who received SNG001 were no more likely to be discharged from the hospital than those who received placebo

In terms of secondary endpoints, patients treated with SNG001 had a 27% and 36% lower relative risk of progression to serious disease or death within 35 days, respectively, compared to patients treated with placebo

Interestingly, in July 2020, Synairgen announced the phase I/II clinical data of SNG001.

(Original abridged)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.